15 results on '"Dognini GP"'
Search Results
2. A woman and her canry: a tale of chlamydiae and lymphomas.
- Author
-
Ferreri AJM, Dolcetti R, Magnino S, Doglioni C, Cangi MG, Pecciarini L, Ghia P, Dagklis A, Pasini E, Vicari N, Dognini GP, Resti AG, and Ponzoni M
- Published
- 2007
- Full Text
- View/download PDF
3. Lower limb myalgias in a man who used to "climb the stairs": an atypical abdominal aortic aneurysm.
- Author
-
Dognini GP, Cadeo G, Dolcino L, Gilardoni L, Stringhi E, and Forloni F
- Subjects
- Aortic Aneurysm, Abdominal diagnosis, Aortic Rupture diagnosis, Emergency Service, Hospital, Humans, Male, Middle Aged, Aortic Aneurysm, Abdominal complications, Aortic Rupture complications, Leg, Musculoskeletal Pain etiology
- Abstract
Atypical presentation of emergency abdominal aortic aneurysm comprises a wide spectrum of symptoms. Lower limbs' involvement is infrequent, usually monolateral and with clear vascular features. We report the case of a 58-year-old patient who complained exclusively about symmetric lower limb myalgias without vascular features, after having repeatedly climbed the stairs of the school he worked in. The surprising final diagnosis was of rupturing abdominal aortic aneurysm; the patient was sent to emergency surgery and survived.
- Published
- 2012
- Full Text
- View/download PDF
4. Telmisartan: just an antihypertensive agent? A literature review.
- Author
-
Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C, and Galli E
- Subjects
- Angiotensin II Type 1 Receptor Blockers economics, Angiotensin II Type 1 Receptor Blockers pharmacology, Animals, Antihypertensive Agents economics, Antihypertensive Agents pharmacology, Atrial Fibrillation prevention & control, Benzimidazoles economics, Benzimidazoles pharmacology, Benzoates economics, Benzoates pharmacology, Costs and Cost Analysis, Humans, Hypertension economics, Hypertension metabolism, Hypertrophy, Left Ventricular prevention & control, Kidney Diseases prevention & control, Renin-Angiotensin System, Telmisartan, Angiotensin II Type 1 Receptor Blockers therapeutic use, Antihypertensive Agents therapeutic use, Benzimidazoles therapeutic use, Benzoates therapeutic use, Hypertension drug therapy
- Abstract
Introduction: The modulation of the renin angiotensin aldosterone system (RAAS) is an important pathway in managing high blood pressure, and its overexpression plays a key role in target end-organ damage. Telmisartan is an angiotensin II receptor blocker (ARB) with unique pharmacologic properties, including the longest half-life among all ARBs; this leads to a significant and 24-h sustained reduction of blood pressure. Telmisartan has well-known antihypertensive properties, but there is also strong clinical evidence that it reduces left ventricular hypertrophy, arterial stiffness and the recurrence of atrial fibrillation, and confers renoprotection., Areas Covered: This paper reviews telmisartan's pharmacological properties in terms of efficacy for hypertension control and, importantly, focuses on its new therapeutic indications and their clinical implications., Expert Opinion: ONTARGET (ongoing telmisartan alone and in combination with ramipril global endpoint trial) demonstrated, that telmisartan confers cardiovascular protective effects similar to those of ramipril, but with a better tolerability. Moreover, recent investigations focused on the capability of telmisartan to modulate the peroxisome proliferator-activated receptor-gamma (PPAR-γ), an established target in the treatment of insulin resistance, diabetes and metabolic syndrome, whose activation is also correlated to anti-inflammatory and, finally, anti-atherosclerotic properties. Telmisartan shows peculiar features that go beyond blood pressure control. It presents promising and unique protective properties against target end-organ damage, potentially able to open a scenario of new therapeutic approaches to cardiovascular disease.
- Published
- 2011
- Full Text
- View/download PDF
5. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial.
- Author
-
Govi S, Dognini GP, Licata G, Crocchiolo R, Resti AG, Ponzoni M, and Ferreri AJ
- Subjects
- Adult, Aged, Aged, 80 and over, Conjunctival Neoplasms drug therapy, Feasibility Studies, Female, Humans, Male, Middle Aged, Treatment Outcome, Antibiotics, Antineoplastic therapeutic use, Clarithromycin therapeutic use, Eye Neoplasms drug therapy, Lymphoma, B-Cell, Marginal Zone drug therapy
- Published
- 2010
- Full Text
- View/download PDF
6. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma.
- Author
-
Ferreri AJ, Dognini GP, Bairey O, Szomor A, Montalbán C, Horvath B, Demeter J, Uziel L, Soffietti R, Seymour JF, Ambrosetti A, Willemze R, Martelli M, Rossi G, Candoni A, De Renzo A, Doglioni C, Zucca E, Cavalli F, and Ponzoni M
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Cyclophosphamide administration & dosage, Disease-Free Survival, Doxorubicin administration & dosage, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prednisone administration & dosage, Proportional Hazards Models, Retrospective Studies, Rituximab, Survival Rate, Vincristine administration & dosage, Anthracyclines therapeutic use, Antibodies, Monoclonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Immunologic Factors therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy, Vascular Neoplasms drug therapy
- Abstract
Some case reports and a Japanese series suggest benefit from the use of rituximab in patients with intravascular large B-cell lymphoma (IVL). Rituximab efficacy was evaluated in Western patients with IVL, comparing outcome of 10 patients treated with rituximab + chemotherapy (R-CT) and of 20 patients treated with chemotherapy alone (CT). There were no significant differences in patients' characteristics between the two subgroups. The addition of rituximab was associated with improved complete remission rate (90% vs. 50%; P = 0.04), event-free survival (3-year: 89% vs. 35%; P = 0.003) and overall survival (3-year: 89% vs. 38%; P = 0.01). In conclusion, rituximab may substantially change the dismal prognosis of IVL.
- Published
- 2008
- Full Text
- View/download PDF
7. Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study.
- Author
-
Ferreri AJ, Dolcetti R, Dognini GP, Malabarba L, Vicari N, Pasini E, Ponzoni M, Cangi MG, Pecciarini L, Resti AG, Doglioni C, Rossini S, and Magnino S
- Subjects
- Adult, Aged, Aged, 80 and over, Animal Husbandry, Case-Control Studies, Chlamydia Infections microbiology, Chlamydophila psittaci genetics, Chronic Disease, Conjunctivitis microbiology, DNA, Bacterial isolation & purification, Environmental Exposure adverse effects, Female, Humans, Leukocytes, Mononuclear microbiology, Male, Middle Aged, Occupational Exposure adverse effects, Polymerase Chain Reaction, Prospective Studies, Risk Factors, Chlamydia Infections complications, Chlamydophila psittaci isolation & purification, Chlamydophila psittaci pathogenicity, Conjunctival Neoplasms microbiology, Conjunctivitis complications, Lymphoma, B-Cell, Marginal Zone microbiology, Orbital Neoplasms microbiology
- Abstract
Ocular adnexal MALT lymphoma (OAML) is linked to Chlamydophila psittaci (Cp) infection. Viability and infectivity of Cp, demonstrated by growth in culture, has not been yet investigated in these patients. We conducted a single-center prospective case-control study to assess the prevalence, viability and infectivity of Cp in 20 OAML patients and 42 blood donors registered in a 6-month period. The presence of Cp in conjunctival swabs and peripheral blood mononuclear cells (PBMC) of patients and donors was assessed by TETR-PCR and in vitro cultures. From an epidemiological point of view, OAML patients often resided in rural areas, and reported a history of chronic conjunctivitis and prolonged contact with household animals (85% vs. 38% of donors; p = 0.00001). Cp was detected in lymphoma tissue in 15 (75%) patients. Cp DNA was detected in conjunctival swabs and/or PBMC from 10 (50%) patients and in PBMC from 1 (2%) donor (p = 0.01). Viability and infectivity of Cp, demonstrated by growth in culture, were confirmed in conjunctival swabs and/or PBMC from 5 (25%) patients, but not in donors (p = 0.002). This prospective study demonstrates, for the first time, that Cp present in the conjunctiva and PBMC of OAML patients is capable to grow and be isolated in cell cultures. Cp infection is common in OAML patients and exceptional in blood donors. Epidemiological data of OAML patients (prolonged contact with household animals and chronic conjunctivitis) are consistent with Cp exposure risk.
- Published
- 2008
- Full Text
- View/download PDF
8. Chlamydia-psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma.
- Author
-
Ferreri AJ, Dognini GP, Ponzoni M, Pecciarini L, Cangi MG, Santambrogio G, Resti AG, De Conciliis C, Magnino S, Pasini E, Vicari N, Dolcetti R, and Doglioni C
- Subjects
- Aged, Aged, 80 and over, Chlamydophila psittaci isolation & purification, Chlamydophila psittaci pathogenicity, Female, Humans, Lymphoma, B-Cell, Marginal Zone complications, Lymphoma, B-Cell, Marginal Zone microbiology, Lymphoma, B-Cell, Marginal Zone pathology, Male, Middle Aged, Orbital Neoplasms complications, Orbital Neoplasms microbiology, Orbital Neoplasms pathology, Psittacosis complications, Remission Induction, Subcutaneous Tissue, Anti-Bacterial Agents therapeutic use, Chlamydophila psittaci drug effects, Doxycycline therapeutic use, Lymphoma, B-Cell, Marginal Zone drug therapy, Orbital Neoplasms drug therapy, Psittacosis drug therapy
- Published
- 2008
- Full Text
- View/download PDF
9. A woman and her canary: a tale of chlamydiae and lymphomas.
- Author
-
Ferreri AJ, Dolcetti R, Magnino S, Doglioni C, Cangi MG, Pecciarini L, Ghia P, Dagklis A, Pasini E, Vicari N, Dognini GP, Resti AG, and Ponzoni M
- Subjects
- Animals, Anti-Bacterial Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bronchial Neoplasms diagnosis, Chlamydophila Infections drug therapy, Chlamydophila Infections microbiology, Chlamydophila Infections veterinary, Doxycycline therapeutic use, Eye Neoplasms drug therapy, Female, Humans, Immunohistochemistry, Liver microbiology, Lymphoma, B-Cell diagnosis, Lymphoma, B-Cell, Marginal Zone drug therapy, Middle Aged, Neoplasms, Second Primary diagnosis, Bird Diseases microbiology, Bronchial Neoplasms microbiology, Canaries microbiology, Chlamydophila Infections transmission, Chlamydophila psittaci isolation & purification, Eye Neoplasms microbiology, Lacrimal Apparatus microbiology, Lymphoma, B-Cell microbiology, Lymphoma, B-Cell, Marginal Zone microbiology, Neoplasms, Second Primary microbiology
- Published
- 2007
- Full Text
- View/download PDF
10. Therapeutic management of ocular adnexal MALT lymphoma.
- Author
-
Ferreri AJ, Assanelli A, Crocchiolo R, Dognini GP, Resti AG, Politi LS, Doglioni C, Cappio FC, Dolcetti R, and Ponzoni M
- Subjects
- Antineoplastic Agents therapeutic use, Eye Neoplasms etiology, Eye Neoplasms pathology, Humans, Lymphoma, B-Cell, Marginal Zone etiology, Lymphoma, B-Cell, Marginal Zone pathology, Eye Neoplasms therapy, Lymphoma, B-Cell, Marginal Zone therapy
- Abstract
Non-Hodgkin lymphomas constitute 50% of all orbital malignancies. Mucosa-associated lymphoid tissue (MALT)-type lymphoma is the most common histology category in this anatomic region. Ocular adnexal lymphoma of MALT-type is an indolent and rarely lethal malignancy that can often be managed with observation alone. Occasionally, lymphomatous lesions determine the symptoms that condition a patient's quality of life, and so require an immediate antineoplastic treatment. Several strategies are available, but reliable indications supported by prospective trials do not exist. Some therapeutic strategies are associated with substantial side effects and require a well-balanced therapeutic decision, which should take into account several variables related to the patient, the lymphoma, and the treatment itself. In this review, the authors analyze related literature and propose therapeutic guidelines for the management of ocular adnexal lymphoma of MALT-type.
- Published
- 2007
- Full Text
- View/download PDF
11. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions.
- Author
-
Ferreri AJ, Dognini GP, Campo E, Willemze R, Seymour JF, Bairey O, Martelli M, De Renz AO, Doglioni C, Montalbán C, Tedeschi A, Pavlovsky A, Morgan S, Uziel L, Ferracci M, Ascani S, Gianelli U, Patriarca C, Facchetti F, Dalla Libera A, Pertoldi B, Horváth B, Szomor A, Zucca E, Cavalli F, and Ponzoni M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anthracyclines therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Asia epidemiology, Asian People statistics & numerical data, Brain Neoplasms epidemiology, Brain Neoplasms ethnology, Brain Neoplasms pathology, Disease Progression, Europe epidemiology, Female, Follow-Up Studies, Forecasting, Humans, Japan ethnology, Lymphohistiocytosis, Hemophagocytic diagnosis, Lymphohistiocytosis, Hemophagocytic ethnology, Lymphohistiocytosis, Hemophagocytic etiology, Lymphoma, Large B-Cell, Diffuse classification, Lymphoma, Large B-Cell, Diffuse complications, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse ethnology, Lymphoma, Large B-Cell, Diffuse pathology, Male, Middle Aged, Organ Specificity, Phenotype, Prognosis, Retrospective Studies, Skin Neoplasms epidemiology, Skin Neoplasms ethnology, Skin Neoplasms pathology, Surveys and Questionnaires, Treatment Outcome, Vascular Neoplasms classification, Vascular Neoplasms complications, Vascular Neoplasms diagnosis, Vascular Neoplasms drug therapy, Vascular Neoplasms ethnology, Vascular Neoplasms pathology, White People statistics & numerical data, Lymphohistiocytosis, Hemophagocytic epidemiology, Lymphoma, Large B-Cell, Diffuse epidemiology, Vascular Neoplasms epidemiology
- Abstract
Background and Objectives: This study explored variations in the clinical manifestations of intravascular lymphoma (IVL) on the bases of the association with hemophagocytosis and the country where the diagnosis was made., Design and Methods: The clinical features of 50 Western patients with IVL were compared with those of 123 patients with IVL diagnosed in Eastern countries (87 diagnosed in Japan and 36 in other Asian countries), previously reported in English literature, and collected by an electronic bibliographic search., Results: Hemophagocytosis was absent in Western patients, but reported in 38 (44%) Japanese patients (p=0.00001) and in seven (19%) patients from other Asian countries (p=0.002). No clinical differences were evident between patients with hemophagocytosis-negative IVL diagnosed in Western countries, Japan and other Asian Countries. Conversely, Japanese and non-Japanese patients with hemophagocytosis-related IVL more frequently had stage IV disease, fever, hepato-splenic involvement, marrow infiltration, dyspnea, anemia, and thrombocytopenia, and rarely exhibited cutaneous or central nervous system involvement. Lymph node and peripheral blood involvement was uncommon in all subgroups. In Western patients, anthracycline-based chemotherapy was associated with a 52% remission rate, and a 2-year overall survival of 46%., Interpretation and Conclusions: The clinical features of IVL vary according to the association with hemophagocytosis, regardless of the country in which the diagnosis is made. Western, Japanese and other Asian patients with hemophagocytosis-negative IVL display similar clinical characteristics and should be considered as having classical IVL. Patients with hemophagocytosis-related IVL show significantly different clinical features. Both forms have a poor prognosis. Extensive molecular studies are needed to explore whether these clinical differences might reflect discordant biological entities within IVL.
- Published
- 2007
- Full Text
- View/download PDF
12. Reply to the article 'Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)' by P. Arnaud, M.-C. Escande, M. Lecuit et al. (Ann Oncol doi:10.1093/annonc/mdl369).
- Author
-
Ferreri AJM, Dolcetti R, Musto P, Dognini GP, Doglioni C, and Ponzoni M
- Published
- 2007
- Full Text
- View/download PDF
13. Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.
- Author
-
Ferreri AJ, Dognini GP, Verona C, Patriarca C, Doglioni C, and Ponzoni M
- Subjects
- Aged, 80 and over, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Murine-Derived, Antigens, CD20 drug effects, Antigens, CD20 genetics, Antigens, Neoplasm drug effects, Antigens, Neoplasm genetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Cyclophosphamide administration & dosage, Epirubicin administration & dosage, Fatal Outcome, Humans, Immunologic Factors pharmacology, Lymphatic Irradiation, Lymphoma, Large B-Cell, Diffuse therapy, Male, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local therapy, Prednisone administration & dosage, Rituximab, Stomach Neoplasms therapy, Vincristine administration & dosage, Antibodies, Monoclonal therapeutic use, Antigens, CD20 biosynthesis, Antigens, Neoplasm biosynthesis, Gene Expression Regulation, Neoplastic, Immunologic Factors therapeutic use, Immunophenotyping, Immunotherapy, Lymphoma, Large B-Cell, Diffuse metabolism, Neoplasm Recurrence, Local metabolism, Stomach Neoplasms metabolism
- Abstract
We report the first case of diffuse large B-cell lymphoma (DLBCL) of the stomach displaying CD20-negative relapse after rituximab-containing treatment and the re-appearance of CD20 expression at the second failure. The loss of CD20 expression in B-cell lymphomas relapsing after rituximab is a well-known phenomenon, but its actual impact in DLBCL is difficult to estimate. This paradigmatic case suggests that CD20-expression reappearance after purging of CD20-positive clones with rituximab might be an underestimated occurrence in B-cell lymphomas. Accordingly, every relapse, whenever possible, should be histologically assessed with diagnostic and immunophenotyping purposes.
- Published
- 2007
- Full Text
- View/download PDF
14. Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial.
- Author
-
Ferreri AJ, Ponzoni M, Dognini GP, Du MQ, Doglioni C, Radford J, Dolcetti R, and Cavalli F
- Subjects
- Anti-Bacterial Agents therapeutic use, Bacteria drug effects, Chlamydia drug effects, Clinical Trials as Topic, Endpoint Determination, Follow-Up Studies, Humans, Prospective Studies, Anti-Bacterial Agents pharmacology, Doxycycline pharmacology, Doxycycline therapeutic use, Eye Neoplasms drug therapy, Eye Neoplasms microbiology, Lymphoma, B-Cell, Marginal Zone drug therapy, Lymphoma, B-Cell, Marginal Zone microbiology
- Published
- 2006
- Full Text
- View/download PDF
15. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.
- Author
-
Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, and Dolcetti R
- Subjects
- Adult, Aged, Chlamydophila psittaci isolation & purification, DNA, Bacterial isolation & purification, Disease-Free Survival, Female, Follow-Up Studies, Humans, Lymphoma, B-Cell, Marginal Zone microbiology, Lymphoma, B-Cell, Marginal Zone pathology, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Orbital Neoplasms microbiology, Orbital Neoplasms pathology, Polymerase Chain Reaction, Prospective Studies, Psittacosis complications, Treatment Outcome, Anti-Bacterial Agents therapeutic use, Antineoplastic Agents therapeutic use, Chlamydophila psittaci drug effects, Doxycycline therapeutic use, Lymphoma, B-Cell, Marginal Zone drug therapy, Orbital Neoplasms drug therapy, Psittacosis drug therapy
- Abstract
Background: An association between ocular adnexal MALT lymphoma (OAL) and Chlamydia psittaci (Cp) infection has been proposed, and recent reports suggest that doxycycline treatment causes tumor regression in patients with Cp-related OAL. The effectiveness of doxycycline treatment in Cp-negative OAL has not been tested., Methods: In a prospective trial, 27 OAL patients (15 newly diagnosed and 12 having experienced relapse) were given a 3-week course of doxycycline therapy. Objective lymphoma response was assessed by computerized tomography scans or magnetic resonance imaging at 1, 3, and 6 months after the conclusion of therapy and every 6 months during follow-up. Cp infection in patients was determined by touchdown enzyme time-release polymerase chain reaction (TETR-PCR). Statistical tests were two-sided., Results: Eleven patients were Cp DNA-positive and 16 were Cp DNA negative. Doxycycline was well tolerated. At a median follow-up of 14 months, lymphoma regression was complete in six patients, and a partial response (> or = 50% reduction of all measurable lesions) was observed in seven patients (overall response rate [complete and partial responses] = 48%). Lymphoma regression was observed in both Cp DNA-positive patients (seven of 11 experienced regression) and Cp DNA-negative patients (six of 16 experienced regression) (64% versus 38%; P = .25, Fisher's exact test). The three patients with regional lymphadenopathies and three of the five patients with bilateral disease achieved objective response. In relapsed patients, response was observed both in previously irradiated and nonirradiated patients. The 2-year failure-free survival rate among the doxycycline-treated patients was 66% (95% confidence interval = 54 to 78), and 20 of the 27 patients were progression free., Conclusions: Doxycycline is a fast, safe, and active therapy for Cp DNA-positive OAL that was effective even in patients with multiple failures involving previously irradiated areas or regional lymphadenopathies. The responses observed in PCR-negative OAL may suggest a need for development of more sensitive methods for Cp detection and investigation of the potential role of other doxycycline-sensitive bacteria.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.